Determining Prognostic Immune Markers in Patients With Ovarian Cancer

This study is collecting blood and tumor tissue samples from women with ovarian cancer — at the time of surgery and during follow-up — to identify immune markers in the tumor environment that may help predict how well patients respond to treatment and how their disease will progress. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with (or are suspected to have) primary or recurrent epithelial ovarian cancer (EOC) and are scheduled for surgery, chemotherapy, or immunotherapy - You are in good general health (WHO performance status 0–2) - You are accessible for ongoing treatment and follow-up visits - You have given written informed consent **You may NOT be eligible if...** - You have had another active cancer in the past 5 years (except treated non-melanoma skin cancer) - You have a known serious infection such as HIV, or hepatitis A, B, or C - You are receiving immune-suppressing medications - You have a medical or psychological condition that would prevent you from completing the study Talk to your doctor to see if this trial is right for you.